2 not yet recruiting, 1 active not recruiting, 1 approved for marketing, 1 completed. 3 Phase 3, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Graves' Orbitopathy: new trials by email Literature Review of Graves' Orbitopathy trials Research Report on Graves' Orbitopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Early Risk Stratification of Thyroid Eye Disease in Newly Diagnosed Graves' Disease Study-related ophthalmological assessment and biospecimen collection, Blood biomarkers and standardized blood samples including thyroid function status - Graves' Orbitopathy, Thyroid Eye Disease, TED | Recruiting | University of Copenhagen | 430 | 2026-10-16 | 2026-10-27 | |
| Microbiota and Immune SignatureS of Graves' Disease and Orbitopathy Aspiration 0 - Graves' Orbitopathy, Graves' Disease | Not applicable | Active not recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 67 | 2025-02-25 | 2026-10-13 |
| A Randomized Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO): the STAGO-2 Study Atorvastatin 20mg, Placebo - Graves' Orbitopathy | Phase 3 | Not yet recruiting | University of Pisa | 102 | 2024-01-01 | 2023-03-15 |
| A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy Methimazole, Radioiodine or thyroidectomy - Graves' Orbitopathy | Phase 3 | Unknown | University of Pisa | 52 | 2023-03-02 | 2023-03-17 |
| Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Teprotumumab, Placebo - Thyroid Eye Disease, Graves' Orbitopathy | Phase 3 | Completed | Amgen | 83 | 2017-10-04 | 2024-07-11 |
| Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease Teprotumumab - Thyroid Eye Disease, Graves' Orbitopathy | Approved for marketing | Amgen | 2024-06-20 |
Graves Ophthalmopathy (7) · Graves Disease (3) · Exophthalmos (2) · Hyperthyroidism (1)
Autoimmune Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Endocrine System Diseases (7) · Eye Diseases (7) · Eye Diseases, Hereditary (7) · Genetic Diseases, Inborn (7) · Goiter (7) · Immune System Diseases (7) · Orbital Diseases (7) · Thyroid Diseases (7) · Hyperthyroidism (6) · Exophthalmos (5) · Graves Disease (4)
Atorvastatin (2) · teprotumumab (2) · Hematologic Tests (1) · Iodine-131 (1) · Lipids (1) · Methimazole (1) · Saline Solution (1) · Thyroidectomy (1)
Amgen (2) · University of Pisa (2) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Region Skane (1) · University of Copenhagen (1)
Italy (4) · United States (2) · Denmark (1) · Germany (1) · Sweden (1)
Birte Nygaard, M.D., Ph.D. (1) · Floriana Bytyqi, M.D (1) · Jens Pedersen, M.D., Ph.D. (1) · Tereza Planck (1)
2017 (1), 2023 (1)